Beth Hinkle Email & Phone Number

La Jolla, Ca

Early Therapeutic Area Lead, Immunology• Mentor and advise NCS Leads in developing the toxicology strategy for Immunology projects covering multiple modalities from the nomination of a target through candidate selection • Partner with Immunology TA leaders to ensure alignment on project goals, issues, and prioritization for the portfolio. Maintain expertise in the represented TA, with a perspective on the evolving internal and external landscape and from different stakeholder views (indications, science of target pathways, diligence, external competitive landscape, regulatory impacts, etc.). • Represent NCS in portfolio governance and business development forums in the Discovery Immunology space

Thousand Oaks, California, United States

• Managed a team providing nonclinical safety assessment for projects that span the Amgen portfolio• Primary point for the strategic interface of CBSS with the Oncology/Inflammation research therapeutic area• Created strategic plans to optimally develop the toxicology strategies for innovative new platforms including bi-specific T cell engagers (BiTEs), biosimilars, and antibody drug conjugates (ADCs) • Scientific leader of nonclinical toxicology programs supporting the safety of biotechnology-derived and small molecule pharmaceutical candidates, from target nomination to post-marketing• Authored nonclinical safety sections of project-related submissions including clinical trial applications, marketing approval applications, investigator brochures, and package insert labels• Developed target liability assessments for projects to investigate the mechanism of action and target expression, select a relevant toxicology species, and identify possible target organs of toxicity • Conducted due diligence in-licensing and out-licensing activities

Santa Barbara, California Area

• Prepared nonclinical safety sections for regulatory submissions to FDA • Established and implemented development strategy of new small molecule therapeutics for toxicity, pharmacodynamics, and efficacy using mouse, rat, guinea pig, and rabbit animal models and mammalian cultured cells• Designed, conducted, and summated in-house safety assessment studies• Created standardized data capture and reporting forms to increase efficiency • Managed Miravant’s hematology and clinical chemistry blood lab• Supervised assistant and associate scientists• Developed and managed the departmental budget

Investigated the effects of alcohol on the brain using biochemical and behavioral approaches in mouse and rat model systems differentially sensitive to alcohol

Doctor Of Philosophy (Ph.D.), Molecular Biology

Identified and characterized proteins that interact with the trkB.T1 truncated receptor and evaluated signal transduction mediated.

Bachelor Of Arts (B.A.), Biology, General

Activities and Societies: with Honors